posted on 2020-02-03, 21:21authored byLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N. CarppLindsay N. Carpp, Kristen W. Cohen, Nadine Rouphael, Llewellyn Fleurs, One Dintwe, Michael Zhao, Zoe Moodie, Youyi Fong, Nigel Garrett, Ying Huang, Craig Innes, Holly E. Janes, Erica Lazarus, Nelson L. Michael, Sorachai Nitayaphan, Punnee Pitisuttuthum, Supachai Rerks-Ngarm, Merlin L. Robb, Stephen C. De Rosa, Lawrence Corey, Glenda E. Gray, Kelly E. Seaton, Nicole L. Yates, M. Juliana McElrath, Nicole Frahm, Georgia D. Tomaras, Peter B Gilbert
Binding antibody multiplex assay (BAMA) and intracellular cytokine staining (ICS) data from HVTN 100, HVTN 097, and RV144. The posted data underlie the vaccine immunogenicity findings in the papers "Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans" by Zhao and Fiore-Gartland et al., 2020 PLOS One; "Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa" by Gray et al., 2019 Sci Trans Med; and "Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial" by Bekker et al., 2018 Lancet HIV.
Funding
HIV Vaccine Trials Network Laboratory Center
National Institute of Allergy and Infectious Diseases